Examination of Tissue from Ablated Malignant Liver Metastases to Predict Outcome


Full Title

Examinations of Tissue from Ablated Malignant Liver Metastases as Predictors of Outcome


In this study, researchers are evaluating a new test to see how well ablation of liver metastases has worked. When some cancers become advanced, particularly colorectal cancer, they may spread to the liver. Destroying the tissue through a needle inserted through the skin — a procedure called “percutaneous ablation” — is one way to treat these metastases in the liver.

Computed tomography(CT) scanning has been used to evaluate the ablated area after treatment. But CT scanning cannot always distinguish between new cancer cells and healthy liver cells that have been affected by the ablation.

With the new approach, liver tissue removed during the ablation procedure is examined in a laboratory to see if researchers can identify any markers that predict the effectiveness of the ablation and how well patients will fare. Patients will be followed for three years after the procedure.

Who Can Join

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have liver metastases (5 cm or less in diameter).
  • Patients must have percutaneous liver ablation instead of surgery as a form of treatment.
  • Patients must be age 18 or older.

For more information and to inquire about eligibility for this study, please contact Dr. Constantinos Sofocleous at 212-639-3379.


Katia Manova-Todorova

ClinicalTrials.gov ID